Log in to search using one of your social media accounts:

 

Woodside Animal Clinic Introduces Oral Cytokine Therapy for Pets
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - May 24, 2015 Category: Pharmaceuticals Source Type: news

Navigating the Treatment Landscape
for Advanced-stage Kidney Cancer Mayer N. Fishman, MD, PhD For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices. The physician must weigh how quickly the cancer is spreading, the pattern of that spread, and relative risks from other medical conditions against the patient’s individual treatment goals and medical needs. In many cases of patients with advanced disease, there are therapies that can realistically be used to meet the goals of longer survival, longer time to disease progression, and tumor shrinkage. While choosing a kidney cancer treatment can be a...
Source: Kidney Cancer Association - December 3, 2014 Category: Urology & Nephrology Source Type: news

Navigating the Treatment Landscape
for Advanced-stage Kidney Cancer Mayer N. Fishman, MD, PhD For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices. The physician must weigh how quickly the cancer is spreading, the pattern of that spread, and relative risks from other medical conditions against the patient’s individual treatment goals and medical needs. In many cases of patients with advanced disease, there are therapies that can realistically be used to meet the goals of longer survival, longer time to disease progression, and tumor shrinkage. While choosing a kidney cancer treatment can ...
Source: Kidney Cancer Association - December 3, 2014 Category: Cancer & Oncology Source Type: news

Cytokine therapy enhances natural killer cell functions against tumor cells
(Journal of Clinical Investigation) A new study in the Journal of Clinical Investigation reveals that cytokine therapy enhances the activity of natural killer cells against tumors lacking MHC class I. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 20, 2014 Category: Cancer & Oncology Source Type: news

Cytokine Inhibition in COPD Published by Dove Medical Press
Specific groups of COPD patients should be targeted with the specific anti-cytokine therapy if there is evidence of high expression of that cytokine, and there are features of the clinical expression...(PRWeb April 29, 2014)Read the full story at http://www.prweb.com/releases/2014/05/prweb11805097.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 29, 2014 Category: Pharmaceuticals Source Type: news

LCNDG Rapid Review: Axitinib as an option for second line advanced renal
Source: London Cancer New Drugs Group Area: Evidence> Drug Specific Reviews Axitinib (Inlyta®, Pfizer) is an orally administered multi-targeted kinase receptor inhibitor that has been licensed in the EU for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine. There are currently no treatments approved by NICE for use in people with advanced RCC who have failed to respond to prior systemic therapy. However, sunitinib and everolimus are occasionally prescribed as second-line treatments through the Cancer Drugs Fund; and are also sugges...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news

Notes from the 8th International Symposium
Patient advocates generously volunteered their time to take notes at the recent 8th International Kidney Cancer Symposium, in Chicago.  These notes are intended to capture the essence of this important medical meeting and convey it in a way that is useful to patients, survivors, and their families.  The first installment sumarizes the Saturday morning session. Integration of Surgical and Systemic Therapy in Metastatic RCC  This session was opened by Dr. Bradley Leibovich who presented two cases on which the audience voted on methods to integrate surgery with systemic treatment interventions.  T...
Source: Kidney Cancer Association - November 17, 2009 Category: Urology & Nephrology Source Type: news

NCCN Guidelines for Kidney Cancer Updated
to Include Pazopanib for Advanced Disease; Free Webinar Discusses Updates The NCCN Guidelines for Kidney Cancer have been updated to incorporate the recently approved therapy pazopanib as a treatment option for patients with advanced renal cell carcinoma. In conjunction with this update, NCCN presents a series of free webinars scheduled for the week of November 9, 2009, hosted by an NCCN Guidelines Panel Member to review the information that supported modification of the NCCN Guidelines. FORT WASHINGTON, PA — Following the recent FDA approval of pazopanib (Votrient™, GlaxoSmithKline) for advanced renal cell ca...
Source: Kidney Cancer Association - November 3, 2009 Category: Urology & Nephrology Source Type: news